-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RyWpun5ETR7SpbxmLaMAXxjbemb71A1yC3t3ZSzqKpGcbhsb4jc18mwuZxpprt7w LyvcRZoJE4sg61m5rxco9A== 0001468246-10-000001.txt : 20100713 0001468246-10-000001.hdr.sgml : 20100713 20100712191018 ACCESSION NUMBER: 0001468246-10-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20100713 DATE AS OF CHANGE: 20100712 EFFECTIVENESS DATE: 20100713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FEMTA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001468246 IRS NUMBER: 262645591 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-144795 FILM NUMBER: 10949021 BUSINESS ADDRESS: STREET 1: 4510 EXECUTIVE DRIVE, SUITE 322 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858.622.0424 MAIL ADDRESS: STREET 1: 4510 EXECUTIVE DRIVE, SUITE 322 CITY: SAN DIEGO STATE: CA ZIP: 92121 D 1 primary_doc.xml X0704 D LIVE 0001468246 FEMTA PHARMACEUTICALS, INC. 4510 EXECUTIVE DRIVE, SUITE 322 SAN DIEGO CA CALIFORNIA 92121 (858) 622-0424 DELAWARE None None Corporation true 2008 Stephen Keane c/o Femta Pharmaceuticals, Inc. 4510 Executive Drive, Suite 322 San Diego CA CALIFORNIA 92121 Executive Officer Director Per Peterson c/o Femta Pharmaceuticals, Inc. 4510 Executive Drive, Suite 322 San Diego CA CALIFORNIA 92121 Director Jay Short c/o Femta Pharmaceuticals, Inc. 4510 Executive Drive, Suite 322 San Diego CA CALIFORNIA 92121 Director Kenneth Widder c/o Femta Pharmaceuticals, Inc. 4510 Executive Drive, Suite 322 San Diego CA CALIFORNIA 92121 Director Jim Woody c/o Femta Pharmaceuticals, Inc. 4510 Executive Drive, Suite 322 San Diego CA CALIFORNIA 92121 Director Pharmaceuticals No Revenues 06 false 2010-06-30 false true true true false 0 2470005 2200005 270000 Warrants to purchase Series A Preferred Stock with an aggregate exercise price of $270,000 were issued in connection with the offering but are unexercised to date. false 5 0 0 0 false FEMTA PHARMACEUTICALS, INC. /s/ Stephen Keane Stephen Keane President, Chief Financial Officer and Secretary 2010-07-12 -----END PRIVACY-ENHANCED MESSAGE-----